Nanoelectrochemistry in electrochemical phase transition reactions.

Electrochemical phase transition is important in a range of processes, including gas generation in fuel cells and electrolyzers, as well as in electrodeposition in battery and metal production. Nucleation is the first step in these phase transition reactions. A deep understanding of the kinetics, and mechanism of the nucleation and the structure of the nuclei and nucleation sites is fundamentally important. In this perspective, theories and methods for studying electrochemical nucleation are briefly reviewed, with an emphasis on nanoelectrochemistry and single-entity electrochemistry approaches. Perspectives on open questions and potential future approaches are also discussed.

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.

Introduction: In Cuba, lung cancer represents the first cause of mortality for both sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85% of NSCLC overexpress EGFR and its ligands. EGFR overexpression has been implicated in the malignant transformation by promoting cell proliferation and survival. CIMAvax-EGF is a therapeutic vaccine composed of recombinant-human EGF conjugated to a carrier protein and Montanide as an adjuvant. CIMAvax-EGF is intended to induce antibodies against self-EGF that block the EGF-EGFR interaction. Objectives: To characterize the efficacy and safety of CIMAvax-EGF as maintenance in NSCLC patients treated in the real-world setting. Results: 106 patients diagnosed with advanced NSCLC at the National Institute of Oncology and Radiobiology, who had at least stable disease after first-line therapy, were enrolled in the study. The initial four CIMAvax-EGF doses were administered every 2 weeks and then, patients received monthly re-immunizations. Globally, 52.8% of the patients were 65 years or older, 77.4% had an ECOG 1 and 62.3% had an adenocarcinoma. The median survival time (MST) was 14.6 months. Patients younger than 65 years had a MST of 16.7 months and subjects with ECOG 0 survived for 29 months. The median progression-free survival was 8.16 months. Overall, 36.8% and 19.8% of patients maintained disease control at 6 and 12 months, respectively. The most frequent adverse events were pain (27.3%) or induration (7.3%) at the injection site and local erythema (10.9%). Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.

Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.

PURPOSE: Dual HER2 blockade chemotherapy is the standard of care for localized HER2+ breast cancer (BC). However, despite the efficacy of neoadjuvant therapy, relapses occurring in around 10% of patients highlight the need to improve its clinical approach. Therefore, this study aimed to evaluate the effectiveness/safety of neoadjuvant therapy with subcutaneous (SC) trastuzumab- pertuzumab chemotherapy (real world) to extend the evidence, which comes mainly from clinical trials (selected population; intravenous [IV] trastuzumab). MATERIALS AND METHODS: A prospective, longitudinal, observational study in a Cuban hospital. POPULATION: women aged ≥18 years with histologically confirmed HER2+ early-stage BC (2017-2021) eligible for neoadjuvant treatment (IV pertuzumab, SC trastuzumab, taxane-based chemotherapy). The aim was to determine the pathological complete response (pCR) rate to this scheme, its safety, and the impact of patient's characteristics on the outcomes. RESULTS: Eighty-seven women were included: n=29 (DPT [docetaxel-IV pertuzumab- SC trastuzumab 600 mg; 4 cycles]); n=58 (ddAC-DPT [dose-dense anthracycline-based scheme+DPT]; 8 cycles). The median age was 57 years (range 30-83), ECOG 0: 97%. Time from diagnosis to treatment (median) was 28 days. The overall pCR rate was 62.1% (55.2%, DPT; 66.5%, ddAC-DPT; p =0.351); HR+, 47.7% vs. HR-, 76.7% (p=0.006). There were no statistically significant differences based on nodal status, stage, or Ki-67 levels. Overall, 94.2% of patients experienced ≥1 adverse event related to treatment, all of them grade 1-3 and more common with ddAC-DPT. The main cause of treatment delays (n=19; ddAC-DPT, 16; DPT, 3) was treatment-related toxicities. CONCLUSION: Neoadjuvant trastuzumab (SC) and pertuzumab plus chemotherapy for HER2+ early-stage BC showed benefits in a real-life setting, with an acceptable safety profile.

Randomized, double-blinded, controlled clinical trial of the effect of captopril, telmisartan and their combination on systemic inflammation of patients on hemodialysis.

To evaluate individual and combined effect of captopril and telmisartan on systemic inflammation markers of hemodialysis (HD) patients. Randomized, double-blinded, controlled clinical trial. Patients on HD at least 2 months, with arteriovenous fistula, were randomly allocated to groups: (1) captopril/placebo (N 13); (2) telmisartan/placebo (N 13); (3) captopril + telmisartan (N 12); or (4) placebo/placebo (N 12). During 3 months, patients received oral drugs as follows: captopril 50 mg/day, telmisartan 80 mg/day or placebo. Patients excluded if they had conditions or were on drugs potentially influencing on inflammation. Clinical and biochemical evaluations were performed monthly. Serum tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), and C-reactive protein (CRP) were measured at 0, 1 and 3 months. Baseline, demographic, clinical and biochemical variables were comparable between groups. Baseline versus final inflammatory markers were: captopril/placebo TNFα, 2.47 (0.1-4.5) versus 1.73 (0.3-3.8) pg/ml; IL-6, 17.03 (7.2-23) versus 7.90 (0.7-19) pg/ml; CRP, 4.21 (1.6-18) versus 5.9 (3.0-28) mg/l; telmisartan/placebo TNFα, 3.03 (2.3-4.6) versus 1.70 (1.2-2.0) pg/ml; IL-6, 14.10 (5.5-23) versus 9.85 (6.2-13) pg/ml; CRP, 5.74 (2.1-13) versus 10.60 (1.5-27) mg/l; captopril + telmisartan TNFα, 1.43 (0.7-5.4) versus 0.40 (0.1-2.1) pg/ml; IL-6, 10.05 (4.9-23) versus 4.00 (0.7-7.7) pg/ml (p < 0.05); CRP, 3.26 (0.7-12) versus 2.83 (0.6-6.5) mg/l; placebo/placebo TNFα, 3.13 (1.6-5.6) versus 1.64 (1.6-2.3) pg/ml; IL-6, 8.12 (5.4-16) versus 7.60 (2.4-15) pg/ml; CRP, 5.23 (1.9-16) versus 3.13 (1.5-18) mg/l. Monotherapy with captopril or telmisartan display a trend, but their combined treatment significantly decreased serum levels of IL-6. No remarkable changes on TNFα and CRP were observed.

Asociación del inmunofenotipo linfocitario de sangre periférica con la presencia de linfomas no Hodgkin / Association of peripheral blood lymphoid immunophenotype with presence of non-Hodgkin lymphomas

Introducción: Los cambios en el inmunofenotipo de los linfocitos en los pacientes con linfoma no Hodgkin están asociados con el pronóstico y las respuestas terapéuticas. Sin embargo, no se ha establecido sistemáticamente la asociación con la enfermedad y por tanto su contribución al diagnóstico. Objetivo: Evaluar la asociación del inmunofenotipo linfocitario en sangre periférica con la presencia del linfoma no Hodgkin. Métodos: Se analizaron 31 muestras de sangre periférica de pacientes con diagnóstico confirmado de linfoma no Hodgkin y de 68 individuos sanos como controles, durante el período de 2018 a 2020. Se empleó la citometría de flujo multiparamétrica para el inmunofenotipado. Se calculó el área bajo la curva y el índice de Youden para establecer puntos de corte en los porcentajes linfocitarios. La asociación de los cambios inmunofenotípicos con el linfoma no Hodgkin, se realizó mediante cálculos de Odd ratio. Resultados: El aumento de linfocitos TCD8+ y NKCD56opaco se asoció significativamente con la presencia de linfoma no Hodgkin (OR= 3,4 y 2,9; respectivamente). Por el contrario, la disminución de linfocitos TCD4+, T doble positivo, T doble negativo y NKCD56brillante también se asoció con la existencia de linfoma no Hodgkin (OR= 23,0; 10,7; 6,9 y 15,8; respectivamente). Además, la disminución del índice CD4/CD8 también fue asociada con la enfermedad. Conclusiones: Los cambios encontrados en los inmunofenotipos linfocitarios se asociaron de forma significativa con la presencia del linfoma no Hodgkin, lo cual representa una expresión sistémica de la enfermedad y sugiere su valor diagnóstico(AU)

Introduction: Lymphocyte immunophenotype changes in non-Hodgkin lymphoma patients are associated with prognosis and therapeutic responses. However, its association with the disease has not been systematically established. Therefor its contribution to the diagnosis process. Objective: To assess the association of lymphocyte immunophenotype in peripheral blood with the presence of non-Hodgkin lymphoma. Methods: 31 peripheral blood samples were analyzed from patients with a confirmed diagnosis of non-Hodgkin lymphoma and from 68 healthy individuals as controls, during the period 2018 to 2020. Multiparametric flow cytometry was used for immunophenotyping. The area under the curve and the Youden index were calculated to establish cut-off points in lymphocyte percentages. The association of immunophenotypic changes with non-Hodgkin's lymphoma was made using Odd ratio calculations. Results: The increase in TCD8+ and NKCD56dim lymphocytes from peripheral blood was significantly associated with the presence of non-Hodgkin lymphoma (OR= 3.4 and 2.9, respectively). Oppositely, the decrease in TCD4+, double positive T, double negative T and NKCD56bright lymphocytes was associated with the existence of non-Hodgkin lymphoma (OR= 23.0, 10.7, 6.9 and 15.8, respectively). Therefore, the decrease in the CD4/CD8 rate was also associated with the disease. Conclusion: The changes found in these lymphocytic immunophenotypes were significantly associated with the presence of non-Hodgkin lymphoma, which represents a systemic expression of the disease and suggests its diagnostic value(AU)

SMILE en linfoma de células NK/T extranodal en recaída / SMILE in relapsed extranodal NK / T cell lymphoma

Introducción: El linfoma extranodal de células NK/T, tipo nasal es una variedad agresiva que se presenta con mayor frecuencia en Asia Oriental y América Latina. El régimen de tratamiento SMILE, basado en dexametasona, metotrexato, ifosfamida, L-asparaginasa y etopósido, mostró tasas de respuestas objetivas adecuadas en estudios de fase 1/2. Objetivo: presentar el primer reporte de la aplicación del protocolo SMILE en Cuba. Presentación del caso: paciente de 47 años de edad, blanca que presentó recaída temprana de linfoma extranodal de células NK/T tipo nasal en partes blandas de la pared anterior izquierda del tórax. Recibió quimioterapia SMILE por 4 ciclos y en la evaluación al final del tratamiento se comprobó que hubo una respuesta completa de la enfermedad(AU)

Introduction: Extranodal lymphoma of NK / T cells, nasal type is an aggressive variety that occurs most frequently in East Asia and Latin America. The SMILE treatment regimen, based on dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide, showed adequate objective response rates in phase 1/2 studies. Objective: to present the first report of the application of the SMILE protocol in Cuba. Case presentation : 47-year-old white patient who presented early relapse of extranodal lymphoma of nasal NK / T cells in soft parts of the left anterior wall of the thorax. He received SMILE chemotherapy for 4 cycles and the evaluation at the end of the treatment showed that there was a complete response of the disease(AU)

Supervivencia de pacientes con linfoma no-Hodgkin y síntomas neurológicos según inmunofenotipo del líquido cefalorraquídeo / Survival in non-Hodgkin´s lymphoma patients with neurological symptoms according to the cerebrospinal fluid immunophenotype

Introducción: Los linfomas no-Hodgkin pueden infiltrar el sistema nervioso central y producir síntomas neurológicos, lo cual incrementa la mortalidad. El diagnóstico de esta infiltración se puede realizar mediante el estudio del líquido cefalorraquídeo por la técnica de citometría de flujo, con una mayor sensibilidad que la citología convencional. Objetivo: Estimar la supervivencia global de pacientes con Linfoma no-Hodgkin y síntomas neurológicos según el inmunofenotipo celular del líquido cefalorraquídeo. Métodos: Se realizó un estudio analítico y prospectivo en 15 pacientes con diagnóstico confirmado de linfoma no-Hodgkin y síntomas neurológicos, con citología negativa del líquido cefalorraquídeo, tratados en el servicio de oncología del Instituto Nacional de Oncología y Radiobiología, durante los años 2017 y 2018. El inmunofenotipo fue caracterizado mediante citometría de flujo multiparamétrica. Resultados: El 60,0 por ciento de los pacientes fue del sexo femenino y el 53,4 por ciento mayor de 60 años. Hubo una mortalidad del 26,7 por ciento. Se realizaron 17 inmunofenotipos, el 58,9 por ciento fue normal, el 23,4 por ciento reactivo y el 17,7 por ciento sospechoso de malignidad. La supervivencia global fue mayor en pacientes con líquido cefalorraquídeo con inmunofenotipo normal (HR. 0.04). Conclusiones: La citometría de flujo pudo discriminar células sospechosas de malignidad, en pacientes cuyas citologías fueron negativas. La presencia en el líquido cefalorraquídeo de células atípicas, de pleocitosis y de un índice de linfocito-monocito alto se asoció con una supervivencia global menor(AU)

Introduction: When non-Hodgkin lymphomas infiltrate the central nervous system increases mortality. The diagnosis of this infiltration can be made by the study of cerebrospinal fluid using flow cytometry, with a higher sensitivity than conventional cytology. Objective: To estimate the relationship between the cellular immunophenotype of the cerebrospinal fluid and the overall survival of patients with non-Hodgkin lymphoma and neurological symptoms. Methods: An analytical and prospective study was conducted in 15 patients with confirmed diagnosis of non-Hodgkin lymphoma and neurological symptoms, with negative cytology of the cerebrospinal fluid. Patients cared at Oncology Department of the National Institute of Oncology and Radiobiology, during the years 2017-2018. The immunophenotype was characterized by multiparametric flow cytometry. Results: 60.0 percent of the patients was female and 53.4 percent older than 60 years. There was an overall mortality of 26.7 percent 17 immunophenotypes were found, 58.9 percent of them was normal, 23.4 percent reactive and 17.7 percent suspected of malignancy. Overall survival advantage was obtained in patients with cerebrospinal fluid with normal immunophenotype (HR 0.04). Conclusions: Flow cytometry could discriminate cells suspected of malignancy, in patients whose cytologies were negative. The presence in the cerebrospinal fluid of atypical cells, pleocytosis and a high lymphocyte-monocyte index were associated with a lower overall survival(AU)

Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).

'Multifocal bone lymphoma' or 'polyostotic lymphoma' is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B-cell lymphoma (MB-DLBCL) registered in a clinico-pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB-DLBCL patients and 63 'controls' (stage-IV DLBCL and skeletal involvement) were analysed. Presentation and treatment of MB-DLBCL and controls were identical. At a median follow-up of 52 months (10-189), MB-DLBCL patients exhibited a significantly better response rate (92% vs. 65%; P = 0·002), progression-free survival (5-year: 56 ± 9% vs. 34 ± 6%; P = 0·003) and overall survival (5-year: 74 ± 8% vs. 36 ± 7%; P = 0·002). Among MB-DLBCL patients, the use of post-chemo radiotherapy was associated with better overall survival (5-year: 83 ± 12% vs. 55 ± 16%; P = 0·003). Two MB-DLBCL patients (5·4%) with spine and skull involvement experienced central nervous system (CNS) relapse. Thus, MB-DLBCL patients exhibit a significantly better prognosis compared to patients with advanced-stage DLBCL, and should be treated with conventional anthracycline-based chemotherapy, keeping intensified treatment for relapsing cases, considering involved-field radiotherapy, and CNS prophylaxis in high-risk patients.

The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).

Indolent lymphomas primarily involving the skeleton (iPBL) represent < 1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5%) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma. Eleven patients had limited stage and 15 had advanced disease. The overall response rate was 73% (95% confidence interval [CI] = 57-89%). Median follow-up was 58 months, and the 5- and 10-year progression-free survival (PFS) rates were 37 ± 10% and 25 ± 12%, respectively. Nine patients are alive, with 5- and 10-year overall survival (OS) rates of 46 ± 10% and 29 ± 11%, respectively. Patients with small lymphocytic lymphoma showed significantly better outcome than patients with follicular lymphoma. Performance status and stage of disease were independently associated with OS. The prognosis of patients with primary bone lymphoplasmacytic or follicular lymphoma was less favorable.

Dermatofibrosarcoma protuberans: presentación de un caso / Dermatofibrosarcoma protuberans: case presentation

El Dermatofibrosarcoma es una neoplasia relativamente rara, de bajo crecimiento, malignidad intermedia, con un alto índice de recurrencia local; siendo las metástasis a distancia extremadamente raras, presentándose sólo en 1% a 5% de los casos, luego de múltiples recidivas locales. Se presentó una paciente con un Dermatofibrosarcoma protuberans en el glúteo derecho, operada, quien posteriormente desarrolló metástasis óseas y pulmonares. Se expone el cuadro clínico y la terapéutica efectuada. Nos propusimos revisar y analizar la evidencia científica disponible en la literatura mundial para determinar las manifestaciones clínicas más frecuentes del Dermatofibrosarcoma, así como los medios diagnósticos más empleados en la actualidad y su potencial metastático.

Dermatofibrosarcoma protuberans is a relatively uncommon soft tissue neoplasm with intermediate-to-low grade malignancy that rarely metastasizes (1-5%) but has a high incidence of local recurrence. A case of Dermatofibrosarcoma protuberans in right gluteus was presented, and after resection of the tumor a lung and bone metastases was discovered. The clinical form of presentation and the treatment are described. We proposed to review and analyze the scientific evidence available in the world literature for determining clinical manifestations most frequent in Dermatofibrosarcoma protuberans as well as diagnostic means widely used in current times.

Dermatofibrosarcoma protuberans: presentación de un caso / Dermatofibrosarcoma protuberans: case presentation

El Dermatofibrosarcoma es una neoplasia relativamente rara, de bajo crecimiento, malignidad intermedia, con un alto índice de recurrencia local; siendo las metástasis a distancia extremadamente raras, presentándose sólo en 1 por ciento a 5 por ciento de los casos, luego de múltiples recidivas locales. Se presentó una paciente con un Dermatofibrosarcoma protuberans en el glúteo derecho, operada, quien posteriormente desarrolló metástasis óseas y pulmonares. Se expone el cuadro clínico y la terapéutica efectuada. Nos propusimos revisar y analizar la evidencia científica disponible en la literatura mundial para determinar las manifestaciones clínicas más frecuentes del Dermatofibrosarcoma, así como los medios diagnós-ticos más empleados en la actualidad y su potencial metastático(AU)

Dermatofibrosarcoma protuberans is a relatively uncommon soft tissue neoplasm with intermediate-to-low grade malignancy that rarely metastasizes (1-5 por ciento) but has a high incidence of local recurrence. A case of Dermatofibrosarcoma protuberans in right gluteus was presented, and after resection of the tumor a lung and bone metastases was discovered. The clinical form of presentation and the treatment are described. We proposed to review and analyze the scientific evidence available in the world literature for determining clinical manifestations most frequent in Dermatofibrosarcoma protuberans as well as diagnostic means widely used in current times(AU)

La Biblioteca universitaria ante los nuevos retos del siglo XXI / University library and the new challenges of the XXI century

Las bibliotecas universitarias se enfrentan a nuevos retos y estilos de trabajo, se transforman y se convierten en centros para el aprendizaje y la investigación. La presente revisión bibliográfica está enfocada hacia los cambios que han marcado el tránsito hacia un nuevo paradigma para la actividad científica-informativa (ACI), con el advenimiento de las nuevas tecnologías de la información y las comunicaciones, los cambios experimentados por los sistemas de la educación superior que condicionan otras formas de enseñaza y aprendizaje en la sociedad del conocimiento y la gestión en el siglo XXI. Se analiza la necesidad de capacitar y desarrollar conocimientos entre los bibliotecarios como parte de un proceso de alfabetización informacional. Se describen algunos estilos de trabajo de estas instituciones que contribuyen a fortalecer el eslabón necesario para la gestión de la información, el conocimiento y el aprendizaje, labor esta que por siglos ha contribuido a la educación y a la formación de nuevos conocimientos. El objetivo fundamental es dar a conocer la labor de las funciones de la biblioteca universitaria y la conversión de esta en una industria de conocimientos ante los nuevos retos del siglo XXI(AU)

University libraries face the new challenges and kind of work of this century and turn into centres for theresearch and learning. This bibliographic review is focused on the changes that have marked the transitionto the new paradigm of scientific-informative activity, with the arrival of information and communicationtechnologies and the transformation of higher education which have an impact on other kinds of teaching and learning process in the information and knowledge society of the XXI century. We discuss the necessity of developing skills and knowledge among the librarians as part of a process of informational alphabetization. Somestyles of work in these institutions are described, which help strengthen the information and knowledgemanagement and the learning process. The main objective is to inform about the work the universitylibrary and its transformation into a knowledge industry facing the challenges of this century(AU)

How changes in the sequence of the peptide CLPFFD-NH2 can modify the conjugation and stability of gold nanoparticles and their affinity for beta-amyloid fibrils.

In a previous work, we studied the interaction of beta-amyloid fibrils (Abeta) with gold nanoparticles (AuNP) conjugated with the peptide CLPFFD-NH2. Here, we studied the effect of changing the residue sequence of the peptide CLPFFD-NH2 on the efficiency of conjugation to AuNP, the stability of the conjugates, and the affinity of the conjugates to the Abeta fibrils. We conjugated the AuNP with CLPFFD-NH 2 isomeric peptides (CDLPFF-NH2 and CLPDFF-NH2) and characterized the resulting conjugates with different techniques including UV-Vis, TEM, EELS, XPS, analysis of amino acids, agarose gel electrophoresis, and CD. In addition, we determined the proportion of AuNP bonded to the Abeta fibrils by ICP-MS. AuNP-CLPFFD-NH2 was the most stable of the conjugates and presented more affinity for Abeta fibrils with respect to the other conjugates and bare AuNP. These findings help to better understand the way peptide sequences affect conjugation and stability of AuNP and their interaction with Abeta fibrils. The peptide sequence, the steric effects, and the charge and disposition of hydrophilic and hydrophobic residues are crucial parameters when considering the design of AuNP peptide conjugates for biomedical applications.

Algunas reflexiones sobre el Melanoma Cutáneo en Cuba / Some thoughts on the Cutaneous Melanoma in Cuba

El melanoma no es una neoplasia frecuente en Cuba; sin embargo, su relación etiológica con factores del ambiente como la radiación ultravioleta de la luz solar, su baja curabilidad cuando es diagnosticado en etapas avanzadas y la implicación de este hecho en la supervivencia de los pacientes aquejados, hace necesaria una atención particular sobre el tema que pueda dar lugar a acciones intervencionistas. Este artículo pretende alertar sobre aspectos negativos que inciden actualmente en la conducta ante los pacientes con esta enfermedad en nuestro medio y que van desde la información a la población, la prevención primaria y secundaria hasta la necesidad de la atención especializada en centros de referencia nacional para la enfermedad o en grupos cooperativos con este propósito(AU)

Incremento del volumen asistencial en el Instituto Nacional de Oncología y Radiobiología entre 1992 y 2000 / Increase of care service at the National Institute of Oncology and Radiobiology from 1992 to 2000

El Instituto Nacional de Oncología (INOR) es el principal centro del país en la atención al paciente oncológico. Se analizaron las características de los casos diagnosticados de cáncer en el INOR entre 1992 y 2000. Se realizó un estudio descriptivo para comparar los casos diagnosticados en los trienios 92-94, 95-97 y 98-2000, mediante un análisis de distribución de frecuencia del número de casos según tiempo, sexo, edad, sitio primario, etapa clínica, tratamiento y base más válida para el diagnóstico. Se halló que la proporción de casos reportados se incrementó en un 65 por ciento en menos de 10 años, predominaron los casos del sexo femenino sobre el masculino 60 vs. 40 por ciento, así como de los pacientes en los grupos de edades mayores de 50 años (68 por ciento) y los casos diagnosticados en etapas tempranas, pero hubo un alto porcentaje de casos sin estadiar (31,2 por ciento). Las principales localizaciones de cáncer fueron piel, cuello de útero, mama, tiroides y laringe. Se evidenció la necesidad de realizar un estudio organizacional del INOR y de la Red Asistencial de Oncología en Ciudad de La Habana, que contemple la priorización de los requerimientos asistenciales en las áreas quirúrgicas y de quimioterapia ambulatoria, haciendo énfasis en las particularidades de las localizaciones de cáncer más frecuentes.

The National Institute of Oncology and Radiobiology (INOR in Spanish) is the main care center for cancer patients in the country. The characteristics of cases diagnosed with cancer at INOR from 1992 to 2000 were analyzed. A descriptive study was carried out to make a comparison among cases diagnosed in the three-year periods 1992-1994, 1995-1997 and 1998-2000 respectively, through a frequency distribution analysis of the number of cases by time, sex, age, primary location, clinical stage, treatment and most valid basis for diagnosis. It was found that number of reported cases increased by 65 percent in less than 10 years; females prevailed over males (60 percent vs 40 percent), over 50 years-old patients and cases diagnosed at early stages of the disease predominated; but there was a high percentage of cases without defined staging (31,2 percent). The main cancer locations were skin, uterus, breast, thyroid and laryx. The need of conducting an organizational study of INOR and the Cancer Care Network in the City of Havana, which will consider the setting of priorities related to care requeriments in surgical areas and in outpatient chemotherapy and will emphasize the particularities of the most frequent cancer locations, was evidenced.

Incremento del volumen asistencial en el Instituto Nacional de Oncología y Radiobiología entre 1992 y 2000 / Increase of care service at the National Institute of Oncology and Radiobiology from 1992 to 2000

El Instituto Nacional de Oncología (INOR) es el principal centro del país en la atención al paciente oncológico. Se analizaron las características de los casos diagnosticados de cáncer en el INOR entre 1992 y 2000. Se realizó un estudio descriptivo para comparar los casos diagnosticados en los trienios 92-94, 95-97 y 98-2000, mediante un análisis de distribución de frecuencia del número de casos según tiempo, sexo, edad, sitio primario, etapa clínica, tratamiento y base más válida para el diagnóstico. Se halló que la proporción de casos reportados se incrementó en un 65 por ciento en menos de 10 años, predominaron los casos del sexo femenino sobre el masculino 60 vs. 40 por ciento, así como de los pacientes en los grupos de edades mayores de 50 años (68 por ciento) y los casos diagnosticados en etapas tempranas, pero hubo un alto porcentaje de casos sin estadiar (31,2 por ciento). Las principales localizaciones de cáncer fueron piel, cuello de útero, mama, tiroides y laringe. Se evidenció la necesidad de realizar un estudio organizacional del INOR y de la Red Asistencial de Oncología en Ciudad de La Habana, que contemple la priorización de los requerimientos asistenciales en las áreas quirúrgicas y de quimioterapia ambulatoria, haciendo énfasis en las particularidades de las localizaciones de cáncer más frecuentes(AU)

The National Institute of Oncology and Radiobiology (INOR in Spanish) is the main care center for cancer patients in the country. The characteristics of cases diagnosed with cancer at INOR from 1992 to 2000 were analyzed. A descriptive study was carried out to make a comparison among cases diagnosed in the three-year periods 1992-1994, 1995-1997 and 1998-2000 respectively, through a frequency distribution analysis of the number of cases by time, sex, age, primary location, clinical stage, treatment and most valid basis for diagnosis. It was found that number of reported cases increased by 65 percent in less than 10 years; females prevailed over males (60 percent vs 40 percent), over 50 years-old patients and cases diagnosed at early stages of the disease predominated; but there was a high percentage of cases without defined staging (31,2 percent). The main cancer locations were skin, uterus, breast, thyroid and laryx. The need of conducting an organizational study of INOR and the Cancer Care Network in the City of Havana, which will consider the setting of priorities related to care requeriments in surgical areas and in outpatient chemotherapy and will emphasize the particularities of the most frequent cancer locations, was evidenced(AU)